Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: A potential early epigenetic susceptibility event in thyroid carcinogenesis

JAMA Surgery

Volumn 149, Issue 11, 2014, Pages 1146-1152

  Brown, Taylor C ^a   Juhlin, C Christofer ^a,b   Healy, James M ^a   Prasad, Manju L ^a   Korah, Reju ^a   Carling, Tobias ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL ARTICLE; CODON; CONFERENCE PAPER; CPG ISLAND; DNA ISOLATION; DNA SEQUENCE; EPIGENETICS; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; ONCOGENE N RAS; PROMOTER REGION; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID HYPERPLASIA; THYROID SURGERY; THYROIDECTOMY; ADENOCARCINOMA; CELL TRANSFORMATION; CHEMISTRY; DNA METHYLATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HYPERPLASIA; MUTATION; PATHOLOGY; PRECANCER; SILENCER ELEMENT; THYROID GLAND; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GTP PHOSPHOHYDROLASES; HUMANS; HYPERPLASIA; MEMBRANE PROTEINS; MUTATION; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; SILENCER ELEMENTS, TRANSCRIPTIONAL; THYROID GLAND; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84911458449     PISSN: 21686254     EISSN: 21686262     Source Type: Journal    
DOI: 10.1001/jamasurg.2014.1694     Document Type: Conference Paper

References (33)

1. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20(5):525-531.
2. Chen AY, Jemal A,Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801-3807.
3. Davies L,Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.
4. XingM. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184-199.
5. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390-3397.
6. Filicori F, Keutgen XM, Buitrago D, et al. Risk stratification of indeterminate thyroid fine-needle aspiration biopsy specimens based on mutation analysis. Surgery. 2011;150(6):1085-1091.
7. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology. 2007;148(3):948-953.
8. Kondo T, Asa SL, Ezzat S. Epigenetic dysregulation in thyroid neoplasia. Endocrinol Metab Clin North Am. 2008;37(2):389-400, ix.
9. Catalano MG, Fortunati N, Boccuzzi G. Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne). 2012;3:40.
10. Fonseca AL, Kugelberg J, Starker LF, et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer. 2012;51(10):949-960.
11. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007;120(pt 18):3163-3172.
12. Elisei R, Shiohara M, Koeffler HP, Fagin JA. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer. 1998;83(10):2185-2193.
13. Alvarez-Nuñez F, Bussaglia E, Mauricio D, et al Thyroid Neoplasia Study Group. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid. 2006;16(1):17-23.
14. Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113(9):2440-2447.
15. Korah R, Healy JM, Kunstman JW, et al. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma. Mol Cancer. 2013;12:87.
16. Lee JJ, Geli J, Larsson C, et al. Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer. Int J Oncol. 2008;33(4):861-869.
17. Santoro A, Pannone G, Carosi MA, et al. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy. J Cell Biochem. 2013;114(5):1174-1182.
18. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002;62(13):3698-3701.
19. XingM, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004;64(5):1664-1668.
20. Hoque MO, Rosenbaum E,Westra WH, et al. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. 2005;90(7):4011-4018.
21. Perez-Montiel MD, Suster S. The spectrum of histologic changes in thyroid hyperplasia: a clinicopathologic study of 300 cases. Hum Pathol. 2008;39(7):1080-1087.
22. Kopp P, Kimura ET, Aeschimann S, et al. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab. 1994;79(1):134-139.
23. Dobosz T, Lukienczuk T, Sasiadek M, Kuczyñska A, Jankowska E, Blin N. Microsatellite instability in thyroid papillary carcinoma and multinodular hyperplasia. Oncology. 2000;58(4):305-310.
24. Arora N, Scognamiglio T, Zhu B, Fahey TJ III. Do benign thyroid nodules have malignant potential? an evidence-based review. World J Surg. 2008;32(7):1237-1246.
25. Xing M, Vasko V, Tallini G, et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab. 2004;89(3):1365-1368.
26. Kunstman JW, Korah R, Healy JM, Prasad M, Carling T. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma. Surgery. 2013;154(6):1255-1261.
27. Lacoste-Collin L, d'Aure D, Bérard E, Rouquette I, Delisle MB, Courtade-Saïdi M. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls. Cytopathology. 2014;25(3):160-169.
28. Sethi K, Sarkar S, Das S, et al. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther Oncol. 2011;9(3):187-199.
29. Park SH, Suh EH, Chi JG. A histopathologic study on 1,095 surgically resected thyroid specimens. Jpn J Clin Oncol. 1988;18(4):297-302.
30. Cerci C, Cerci SS, Eroglu E, et al. Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med. 2007;53(3):157-160.
31. Rodríguez-Rodero S, Fernández AF, Fernández-Morera JL, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab. 2013;98(7):2811-2821.
32. Ellis RJ,Wang Y, Stevenson HS, et al. Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab. 2014;99(2):329-337.
33. Pacifico F, Mauro C, Barone C, et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem. 2004;279(52):54610-54619.